mhurhangee/ep-ind-claims huggingface dataset:
A method for continuously producing a rubber masterbatch, comprising the following steps: step: adding a filler in a rubber solution, and stirring to form a rubber/filler/solvent mixture; step: removing the solvent, and drying said mixture to obtain a rubber/filler masterbatch; wherein, said drying in step 2) is that the mixture obtained in step 1) is transferred to a heating conveyor belt dryer, and heated and dried under vacuum or an inert gas, the volatilized solvent and the unreacted monomer in the synthesis of rubber enter into a condenser and a fractionation column for recovery; alternatively, said drying in step 2) is that the mixture obtained in step 1) is spray dried or flashed, the heating medium used is an inert gas or water vapor, and the volatilized solvent and the unreacted monomer in the synthesis of rubber enter into the condenser and the fractionation column for recovering, wherein the step specifically comprises adding the filler into the rubber solution, stirring to form a rubber/filler/solvent mixture, as well as further finely and refinedly dispersing the rubber/filler/solution mixture to improve the dispersity of the filler in the rubber solution; and wherein said fine dispersion is implemented by the following way: the mixture obtained after stirring is injected by a nozzle at high pressure under the condition of high shear, to improve the dispersion of filler and/or additive; the ejected material is rendered to pass through a multi-elbow pipe to make mixed solution collided with the wall of the tube in the tube, resulting in the increased dispersion of the filler and/or the additive; or the ejected material is rendered to pass through a pipe having varying inner diameters so as to change shear stress, resulting in the increased dispersion of the filler and/or the additive. step: adding a filler in a rubber solution, and stirring to form a rubber/filler/solvent mixture; step: removing the solvent, and drying said mixture to obtain a rubber/filler masterbatch;
A ventilation duct comprising a tubular segment having a longitudinal axis of extension and a pair of ends located along the longitudinal axis of extension, said tubular segment being longitudinally opened and having two edges adapted to be drawn near each other and to be joined together during an installation of the duct; a pair of flanges each located at a respective end and extending transversely to the longitudinal axis of extension, each flange having a plurality of breaks along a perimeter of the tubular segment, characterized in that each break is in the shape of a "V" converging in the direction of the longitudinal axis of extension, whereby each break is suitable for opening wide said edges without warping said flanges, in such a way as to insert one duct into another.
A method for use in a wireless device affected by pre-emption, the method comprising: receiving (404, 1104, 1204, 1304), from a network node, information indicating a portion of a buffer that is affected by pre-emption; and performing (408, 1108, 1208, 1308) one or more operations based on the received information; wherein the information indicating the portion of the buffer that is affected by pre-emption comprises a bitfield, each bit indicating whether a corresponding Orthogonal Frequency Division Multiplexing, OFDM, symbol has been pre-empted, characterized in that the information indicating the portion of the buffer that is affected by pre-emption indicates two or more carriers affected by pre-emption. receiving (404, 1104, 1204, 1304), from a network node, information indicating a portion of a buffer that is affected by pre-emption; and performing (408, 1108, 1208, 1308) one or more operations based on the received information; wherein the information indicating the portion of the buffer that is affected by pre-emption comprises a bitfield, each bit indicating whether a corresponding Orthogonal Frequency Division Multiplexing, OFDM, symbol has been pre-empted, characterized in that the information indicating the portion of the buffer that is affected by pre-emption indicates two or more carriers affected by pre-emption.
A control device for a servo motor that operates a control target, the control device comprising a feedforward controller configured to output a model position, a model velocity, and a model torque based on a preset model of the control target, the model position, the model velocity, and the model torque being target values of a position, a velocity, and a torque of the servo motor, wherein the feedforward controller comprises a sliding mode controller configured to determine, based on a model position deviation that is a deviation between an externally input position command value and the model position and a model velocity deviation that is a deviation between a velocity command value and the model velocity, the model torque such that the model position deviation and the model velocity deviation converge onto a switching curve determined by a predetermined torque that can be output from the servo motor and a motion characteristic of a load machine driven by the servo motor, the motion characteristic is an inertia moment of the load machine and a viscosity coefficient, and the switching curve is defined as a sum of a logarithmic curve and a straight line in a plane defined with the model position deviation and the model velocity deviation.
A gas turbine engine comprising: a spool; a turbine coupled to drive the spool; a propulsor coupled to be driven by said turbine through said spool; and a gear assembly coupled between said propulsor and said spool such that rotation of said spool drives said propulsor at a different speed than said spool, wherein said propulsor includes a hub and a row of propulsor blades that extend from said hub, and said row includes a number of said propulsor blades, wherein each of said propulsor blades extends radially between a root and a tip and in a chord direction between a leading edge and a trailing edge at the tip to define a chord dimension, said row of propulsor blades defining a circumferential pitch with regard to said tips, and wherein the number of blades is 12 or 14; characterised in that: said row of propulsor blades has a solidity value of CD/CP that is between 1.1 and 1.3. a spool; a turbine coupled to drive the spool; a propulsor coupled to be driven by said turbine through said spool; and a gear assembly coupled between said propulsor and said spool such that rotation of said spool drives said propulsor at a different speed than said spool, wherein said propulsor includes a hub and a row of propulsor blades that extend from said hub, and said row includes a number of said propulsor blades, wherein each of said propulsor blades extends radially between a root and a tip and in a chord direction between a leading edge and a trailing edge at the tip to define a chord dimension, said row of propulsor blades defining a circumferential pitch with regard to said tips, and wherein the number of blades is 12 or 14; characterised in that: said row of propulsor blades has a solidity value of CD/CP that is between 1.1 and 1.3.
A checkpoint kinase 1 inhibitor selected from the group consisting of -N-(4-(3-aminopiperidin-1-yl)-5-bromo-1H-pyrrolo[2,3-b]pyridin-3-yl)nicotinamide; -N-(4-(3-aminopiperidin-1-yl)-5-bromo-1H-pyrrolo[2,3-b]pyridin-3-yl)isobutyramide; -N-(5-bromo-4-(3-(methylamino)piperidin-1-yl)-1H-pyrrolo[2,3-b]pyridin-3-yl)nicotinamide; -N-(4-(3-aminopiperidin-1-yl)-5-bromo-1H-pyrrolo[2,3-b]pyridin-3-yl)-5-methylnicotinamide; -N-(4-(3-aminopiperidin-1-yl)-5-bromo-1H-pyrrolo[2,3-b]pyridin-3-yl)cyclopropanecarboxamide; -N-(4-(3-aminopiperidin-1-yl)-5-bromo-1H-pyrrolo[2,3-b]pyridin-3-yl)-3-methylbutanamide; and -N-(4-(3-aminopiperidin-1-yl)-5-bromo-1H-pyrrolo[2,3-b]pyridin-3-yl)-2-cyclopropylacetamide, for administration to a patient with cancer for use in potentiating a DNA damaging agent in a method for treating cancer, wherein the administration of the CHK1 inhibitor follows the administration of the DNA damaging agent, wherein the CHK1 inhibitor is administered in two doses, the first dose of the CHK1 inhibitor is administered one day after the DNA damaging agent, and the second dose of the CHK1 inhibitor is administered two days after the DNA damaging agent.
A lighting apparatus, comprising: a first substrate comprising a lighting portion and outer portions (NA1,NA2) arranged along an outer circumference of the lighting portion, the outer portions (NA1, NA2) including a first outer portion and a second outer portion; an organic light emitting device comprising from the first substrate a first electrode, an organic light emitting layer, and a second electrode, disposed in the lighting portion and a partial region of at least one of the first outer portion and the second outer portion of the substrate; at least one first pad disposed on the first outer portion and integrally formed with the first electrode, and at least one second pad disposed on the second outer portion, the at least one second pad being formed on the same layer as the at least one first pad and electrically connected to the second electrode through a contact hole formed in the organic light emitting layer and' an auxiliary electrode disposed in the lighting portion and the first and second outer portions (NA1, NA2) of the first substrate, wherein the auxiliary electrode is provided under the first electrode (124, 123a) in the lighting portion and the first outer portion and is provided under the second pad and insulated therefrom in the second outer portion, the auxiliary electrode being connected to the first electrode in the lighting portion and the first outer portion, wherein the contact hole is formed over the auxiliary electrode in the second outer portion. a first substrate comprising a lighting portion and outer portions (NA1,NA2) arranged along an outer circumference of the lighting portion, the outer portions (NA1, NA2) including a first outer portion and a second outer portion; an organic light emitting device comprising from the first substrate a first electrode, an organic light emitting layer, and a second electrode, disposed in the lighting portion and a partial region of at least one of the first outer portion and the second outer portion of the substrate; at least one first pad disposed on the first outer portion and integrally formed with the first electrode, and at least one second pad disposed on the second outer portion, the at least one second pad being formed on the same layer as the at least one first pad and electrically connected to the second electrode through a contact hole formed in the organic light emitting layer and' an auxiliary electrode disposed in the lighting portion and the first and second outer portions (NA1, NA2) of the first substrate, wherein the auxiliary electrode is provided under the first electrode (124, 123a) in the lighting portion and the first outer portion and is provided under the second pad and insulated therefrom in the second outer portion, the auxiliary electrode being connected to the first electrode in the lighting portion and the first outer portion, wherein the contact hole is formed over the auxiliary electrode in the second outer portion.
A surgical stapling instrument, comprising: an elongate shaft assembly defining a shaft axis (SA-SA); a surgical end effector operably coupled to said elongate shaft assembly by an articulation joint such that said surgical end effector is selectively articulatable relative to said elongate shaft assembly about an articulation axis (B-B) that is transverse to said shaft axis, said surgical end effector comprising a cartridge support member that is configured to operably support a surgical staple cartridge therein; a longitudinally movable firing beam extending through said articulation joint and being selectively axially movable from a starting position to an ending position within said surgical end effector; and a firing beam locking assembly comprising a biasing member being configured to apply a biasing motion to said longitudinally movable firing beam to bias said longitudinally movable firing beam into a locked position wherein said longitudinally movable firing beam is prevented from moving from said starting to said ending position unless an unfired surgical staple cartridge is operably supported in said cartridge support member, characterized in that the biasing member is operably supported on the articulation joint. an elongate shaft assembly defining a shaft axis (SA-SA); a surgical end effector operably coupled to said elongate shaft assembly by an articulation joint such that said surgical end effector is selectively articulatable relative to said elongate shaft assembly about an articulation axis (B-B) that is transverse to said shaft axis, said surgical end effector comprising a cartridge support member that is configured to operably support a surgical staple cartridge therein; a longitudinally movable firing beam extending through said articulation joint and being selectively axially movable from a starting position to an ending position within said surgical end effector; and a firing beam locking assembly comprising a biasing member being configured to apply a biasing motion to said longitudinally movable firing beam to bias said longitudinally movable firing beam into a locked position wherein said longitudinally movable firing beam is prevented from moving from said starting to said ending position unless an unfired surgical staple cartridge is operably supported in said cartridge support member, characterized in that the biasing member is operably supported on the articulation joint.
A bone biospecific agent comprising a contrast material core, which is visible using Magnetic Resonance Imaging or Computed Tomography, wherein: i) the contrast material core comprises a magnetic material or gold and is surrounded by a polymeric shell, wherein the polymeric shell is functionalised with a bone-targeting peptide, wherein the bone-targeting peptide comprises a peptide selected from SEQ ID No.1-15; or ii) wherein the contrast material core comprises gadolinium and the core is functionalised with a bone targeting peptide, wherein the bone targeting peptide comprises SEQ ID No.3, and wherein the agent further comprises 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA), wherein the peptide, in use, targets the biospecific agent to bone, and wherein the peptide mimics proteins participating in the inhibition of osteoclast-osteoclast and/or osteoclast-osteoblast interactions, or recognises the mineral phase of bone. i) the contrast material core comprises a magnetic material or gold and is surrounded by a polymeric shell, wherein the polymeric shell is functionalised with a bone-targeting peptide, wherein the bone-targeting peptide comprises a peptide selected from SEQ ID No.1-15; or ii) wherein the contrast material core comprises gadolinium and the core is functionalised with a bone targeting peptide, wherein the bone targeting peptide comprises SEQ ID No.3, and wherein the agent further comprises 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA), wherein the peptide, in use, targets the biospecific agent to bone, and wherein the peptide mimics proteins participating in the inhibition of osteoclast-osteoclast and/or osteoclast-osteoblast interactions, or recognises the mineral phase of bone.
A switch device for operating as an intermediate node in a Time Sensitive Network, TSN, comprising: a storage unit storing a configuration indicating for a flow a timing in which a frame pertaining to the flow is to be output; and a processing circuitry configured to: receive a frame pertaining to the flow, in a case where the frame is to be transmitted at a current time according to the configuration, transmit the frame at the current time, and, otherwise, do not transmit the frame at the current time; the processing circuitry further being configured to check whether the switch device is about to send the right frame according to the configuration and if there is a frame to be sent not according to the configuration the switch device will be idle instead of sending a different frame than intended. a storage unit storing a configuration indicating for a flow a timing in which a frame pertaining to the flow is to be output; and a processing circuitry configured to: receive a frame pertaining to the flow, in a case where the frame is to be transmitted at a current time according to the configuration, transmit the frame at the current time, and, otherwise, do not transmit the frame at the current time; the processing circuitry further being configured to check whether the switch device is about to send the right frame according to the configuration and if there is a frame to be sent not according to the configuration the switch device will be idle instead of sending a different frame than intended. receive a frame pertaining to the flow, in a case where the frame is to be transmitted at a current time according to the configuration, transmit the frame at the current time, and, otherwise, do not transmit the frame at the current time; the processing circuitry further being configured to check whether the switch device is about to send the right frame according to the configuration and if there is a frame to be sent not according to the configuration the switch device will be idle instead of sending a different frame than intended.
A process for separating an organofluorine compound from a composition, comprising: contacting a feed stream comprising at least one first unsaturated organofluorine compound selected from the group consisting of HFO-1234yf, HFO-1234ze, HFO-1243zf, HCFO-1233xf and mixtures thereof, and at least one additional compound selected from HF with a semipermeable membrane comprising at least one polymer selected from the group consisting of polypropylene, polyvinylidene fluoride, to form a first stream rich in the at least one organofluorine compound.
A process for the production of a polymer from one or more monomer, the process comprising the steps of: a) preparing an FDCA monomer by converting one or more furanic precursor of 2,5-furandicarboxylic acid (FDCA) to FDCA, by reaction with an oxidant in the presence of an oxidoreductase catalyst and optionally one or more coenzyme, characterised in that the oxidoreductase catalyst comprises a polypeptide comprising an amino acid sequence having at least 60% sequence identity with SEQ ID NO: 3, wherein the oxidoreductase catalyst is a whole cell biocatalyst that is a cell comprising an expression construct for expression of a nucleotide sequence encoding an oxidoreductase having an amino acid sequence with at least 60% identity with the amino acid sequence of SEQ ID NO: 3, wherein, said expression construct is expressible in said cell and expression thereof confers to or increases in the cell the ability to oxidize 5-hydroxymethylfurfural and 5-hydroxymethyl-2-furancarboxylic acid (HMF acid) to 2,5-furandicarboxylic acid (FDCA), as compared to a corresponding wild type cell lacking the expression construct; and, b) producing a polymer from one or more monomer, wherein one of the monomer is the FDCA monomer produced in a). a) preparing an FDCA monomer by converting one or more furanic precursor of 2,5-furandicarboxylic acid (FDCA) to FDCA, by reaction with an oxidant in the presence of an oxidoreductase catalyst and optionally one or more coenzyme, characterised in that the oxidoreductase catalyst comprises a polypeptide comprising an amino acid sequence having at least 60% sequence identity with SEQ ID NO: 3, wherein the oxidoreductase catalyst is a whole cell biocatalyst that is a cell comprising an expression construct for expression of a nucleotide sequence encoding an oxidoreductase having an amino acid sequence with at least 60% identity with the amino acid sequence of SEQ ID NO: 3, wherein, said expression construct is expressible in said cell and expression thereof confers to or increases in the cell the ability to oxidize 5-hydroxymethylfurfural and 5-hydroxymethyl-2-furancarboxylic acid (HMF acid) to 2,5-furandicarboxylic acid (FDCA), as compared to a corresponding wild type cell lacking the expression construct; and, b) producing a polymer from one or more monomer, wherein one of the monomer is the FDCA monomer produced in a).
Element for manufacturing a binding folder or for manufacturing a display board, whereby the element is a semi-finished product that is primarily flat and primarily formed by a support that is formed by or composed of one or more flat sheets and a cover that is affixed over or around the sheet or sheets, whereby on one side the support is provided with a layer of hot-melt adhesive, to affix a finishing cover or a poster or similar on said side of the support, characterised in that the layer of hot-melt adhesive extends up to a distance from the edges of the support.
A substantially clear nutritional liquid comprising calcium HMB in an amount ranging from 1/600 to 1/80 g/mL and protein and having a pH of from 2.8 to 4.6, wherein from 65% to 100% by weight of total protein in the nutritional liquid is soluble protein, wherein the weight ratio of calcium HMB to soluble calcium is from 4.5:1 to 7.3:1, and wherein the nutritional liquid is shelf-stable.
Method of self-assembly including self-alignment of components on a substrate on the basis of surface tension of liquid solder, involving a solder stack on said substrate, said solder stack being composed of an outermost layer of solder on top and at least another layer of solder between said outermost layer of solder and said substrate, the layers of solder having successively increasing melting points from top to bottom, the method comprising the steps of: i) dispensing the components in a first fluid, the first fluid being heated to a temperature below its boiling point but above the melting point of the outermost layer of solder, thereby heating the solder stack to a temperature between the melting point of the outermost layer of solder and the at least another layer of solder to form a selective adhesive to capture the components, ii) using the molten outermost layer to form a receptor which adheres to the components, resulting in the self-assembly, self-alignment, and attachment of the components, iii) heating the solder stack to a temperature above the melting point of the at least another layer of solder, thereby iv) initialising a reflow soldering-process of the outermost and the at least another layer of solder (3, 4) to form a mixed solder layer as an alloy to form an interconnect between the components and the substrate with a melting point higher than that of the outermost layer of solder. i) dispensing the components in a first fluid, the first fluid being heated to a temperature below its boiling point but above the melting point of the outermost layer of solder, thereby heating the solder stack to a temperature between the melting point of the outermost layer of solder and the at least another layer of solder to form a selective adhesive to capture the components, ii) using the molten outermost layer to form a receptor which adheres to the components, resulting in the self-assembly, self-alignment, and attachment of the components, iii) heating the solder stack to a temperature above the melting point of the at least another layer of solder, thereby iv) initialising a reflow soldering-process of the outermost and the at least another layer of solder (3, 4) to form a mixed solder layer as an alloy to form an interconnect between the components and the substrate with a melting point higher than that of the outermost layer of solder.